🔗 Share this article

As the United States undertakes historic changes to its immunization guidelines, one figure appears in a surprising turn: Tracy Beth Høeg, a Danish American physician and public health researcher who first made her name by casting doubt on Covid vaccinations during the pandemic and has focused upon possible fatalities after Covid vaccination in her recent tenure at the Food and Drug Administration.

Planned Overhauls to Pediatric Vaccine Program

Health officials planned to reveal major changes to the childhood immunization program earlier this month, bringing the US with Denmark’s immunization schedule, according to reports – a substantial departure that would place the US out of alignment with a large portion of the global community with insufficient data for improved outcomes. This reveal has been delayed until the coming year.

In place of the top vaccines chief, Tracy Beth Høeg is scheduled to present at the meeting. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth individual to head the division this calendar year.

A Shift at the Regulatory Body

Høeg's temporary position may indicate a tighter collaboration between the pharmaceutical and biologics centers as Høeg and Prasad strengthen their influence at the FDA – and it signals a renewed priority upon rolling back previously authorized vaccines at the FDA.

Dr. Høeg has repeatedly called for ending some pediatric vaccine recommendations in the US so as to align more in line with Denmark, a society with nationalized medicine and a population roughly the size of Wisconsin’s.

In her initial statements, she has kept her attention on immunizations – typically the domain of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Questions Over Expertise

Høeg has no apparent experience in drug development, approval processes or administrative roles, which has been typical for past heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the commissioner and the vaccine center since spring.

“It seems she lacks to have the requisite experience” for running the drug-regulation department, said Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in leading a large organization. She is not an expert in pharmaceutical oversight.”

Past heads of the center would “be deeply familiar with legal statutes and the underlying principles of drug development”, noted a former acting FDA commissioner. “Frankly, she lacks the type of experience that prior appointees who headed CBER have had.”

CDER has an enormous range of responsibilities at the agency, the former commissioner pointed out.

“Everybody just zeroes in on the novel medication approvals, but the generic program clears thousands of generic drugs. There is also a biosimilars program, OTC medication office and so forth, and each of these need to be looked after,” Woodcock explained. “The responsibility you overlook, that is the part that I always told people is going to cause problems.”

Furthermore, a substantial management aspect to the position, which oversees over 5,000 employees. “It is a massive leadership role, if you do it right,” she concluded.

Official Statement and Disputed Initiatives

When asked about questions about Dr. Høeg's qualifications and whether this selection signifies greater collaboration among regulatory chiefs on immunizations, a press secretary said that the “inquiries are based on flawed presumptions”.

“Her resume matches the responsibilities of her job,” the official explained, pointing to the period Dr. Høeg spent counseling the FDA commissioner on “medication safety and oversight research, including computerized risk analysis and shot safety tracking”.

As acting director, Høeg assumes responsibility for the commissioner’s controversial fast-track approval initiative, a contentious expedited drug-approval program that reportedly concerned her predecessors. “How are these therapies being picked for this fast-track system? Who makes the decisions?” Dr. Howard said. “There’s a lot of confidentiality happening at the agency right now.”

Broadly speaking, he stated, “the agency seems to be moving towards more relaxed oversight of all drugs, aside from shots.”

Established History on Immunizations

Regarding vaccines, Høeg has a clearer, if concerning, past, critics observe. She published a study using unverified crowd-sourced reports to assess the frequency of heart inflammation following COVID-19 immunization. She consulted for the state of Florida top health official Joseph Ladapo, who allegedly have altered data to suggest COVID-19 vaccines are riskier than they are.

Included in her “desired changes” for the incoming federal leadership featured changing guidelines for novel immunizations and ending “optional” vaccines, she remarked after the election on a online show. At the agency, Dr. Høeg has according to sources proposed barring young men from obtaining COVID-19 vaccines.

“She is an thorough dogmatist who begins with her conclusions and tailors the evidence to accommodate the science in a extremely deceptive, untruthful manner,” Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg aligned with other skeptics, {like|